NASDAQ · INCY
Incyte Corporation
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
Loading market information…
NASDAQ · COGT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cogent Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cogent Biosciences, Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$0.56. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cogent Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Feb 25, 2025 | -$0.61-3.39% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.64-16.36% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $53.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
$22.53+$0.30 (+1.35%)
Tango Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.49% below the high.
$32.89-$1.07 (-3.15%)
IDEAYA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.94% below the high.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$18.61+$0.22 (+1.2%)
Arcus Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.37% below the high.
$31.93+$0.20 (+0.63%)
Maze Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.48% below the high.
$14.15-$0.17 (-1.19%)
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.7% below the high.
$10.56-$0.16 (-1.49%)
Kura Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.03% below the high.
